Just a moment, the page is loading...
Notice to Investigators involved in Pure Substance Request studies: Due to temporary supply issues, there may be a delay in the processing or shipping of pure substances at this time. We apologize for the inconvenience, and we appreciate your understanding.
♥




Advancing Evidence in HIV Treatment: Using other VH Product besides Cabotegravir and Dolutegravir/Lamivudine (General)

ViiV Healthcare welcomes investigator-sponsored research that advances understanding of HIV treatment using other VH products besides Cabotegravir and Dolutegravir/Lamivudine. Research of interest may include real-world effectiveness, safety and tolerability, patient and provider experience, quality of life, healthcare resource use, economic value, and health equity. We encourage innovative approaches and studies across diverse populations that can expand real-world knowledge and inform clinical practice.






ViiV ISR Area Of Interest Overview

Drug/Product Alignment
Other
Treatment
Area of Interest/DataGap Description
Open
All scientifically sound and relevant research questions that advance evidence in HIV treatment using other VH products besides Cabotegravir and Dolutegravir are welcome.
Desirable Study Parameters
All Patient Types
Global

Version 20250909-disp



- Back to Top -
© 2026 ViiV Healthcare
Trademarks are owned by or licensed to the ViiV Healthcare group of companies